SPY389.63+0.17 0.04%
DIA312.42-0.01 0.00%
IXIC11,354.62-33.88 -0.30%

BRIEF-Horizon Therapeutics Says Received European Commission Approval Of Uplizna

reuters.com · 05/02/2022 01:05
BRIEF-Horizon Therapeutics Says Received European Commission Approval Of Uplizna

- Horizon Therapeutics PLC HZNP:

  • HORIZON THERAPEUTICS PLC RECEIVES EUROPEAN COMMISSION (EC) APPROVAL OF UPLIZNA® (INEBILIZUMAB) FOR THE TREATMENT OF ADULTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)

  • HORIZON THERAPEUTICS - EC APPROVAL SUPPORTED BY RESULTS FROM N-MOMEMTUM, SHOWED 87.6% OF AQP4-IGG+ NMOSD PATIENTS ON UPLIZNA WERE ATTACK FREE FOR 28 WEEKS

Source text for Eikon: ID:nBw609tsJa

Further company coverage: HZNP


((reuters.briefs@thomsonreuters.com;))